57463-14-6

Upstream product

• 95-85-2 2-hydroxy-5-chloro-aniline 
• 19078-72-9 bromo(phenyl)acetyl chloride 
• 2912-62-1 α-chlorophenylacetyl chloride 
• 339559-24-9 2-chloro-N-(5-chloro-2-hydroxy-phenyl)-2-phenyl-acetamide 

Downstream Products

• 57462-98-3 6-chloro-4-(2,3-dihydroxy-propyl)-2-phenyl-4H-benzo[1,4]oxazin-3-one 
• 1050293-89-4 (R/S)-6-chloro-2-phenyl-3-(pyridin-3-ylamino)-2H-1,4-benzoxazine 
• 944356-18-7 6-chloro-2-phenyl-3,4-dihydro-2H-benzo[1,4]oxazine 

Relevant academic research and scientific papers

Molecular determinants for the activating/blocking actions of the 2H-1,4-benzoxazine derivatives, a class of potassium channel modulators targeting the skeletal muscle KATP channels

The 2H-1,4-benzoxazine derivatives are modulators of the skeletal muscle ATP-sensitive-K+ channels (KATP), activating it in the presence of ATP but inhibiting it in the absence of nucleotide. To investigate the molecular determinants

Carboxylic Acid Compounds and Use Thereof

Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: [image] wherein each symbol is as defined in the specification.

Synthesis and pharmacological activity of 4 substituted 2,3 dihydro 1,4 benzoxazin 3 ones

Some derivatives of 3 oxo 2,3 dihydro 1,4 benzoxazine substituted with aminoalkyl and hydroxyalkyl groups were prepared and their analgesic activity studied. This was weak for the amino, but very important for the propranediol derivatives. One of them, AN